·tradingview.comLow
NDRA Q3'26 Earnings: EPS estimate is (0.84) USD
ENDRA Life Sciences (NDRA) will report Q3'26 earnings on November 16. Analysts expect $0 revenue and a loss of $0.84 per share.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$NDRA
ENDRA Life Sciences Inc.
ENDRA Life Sciences develops TAEUS, a thermo-acoustic enhanced ultrasound platform. Its initial focus is a device for assessing liver fat, intended for use in metabolic disease screening and monitoring. The system combines radio-frequency energy with ultrasound sensors and proprietary algorithms to estimate liver fat, and is designed to work with a conventional ultrasound scanner. ENDRA targets pharmaceutical companies and clinical research organizations, high-end primary care networks, bariatric and metabolic clinics, and primary and internal medicine practices. It plans to offer multi-year subscriptions as well as equipment sales with related service and upgrades, and may license TAEUS to equipment makers. The company is headquartered in Ann Arbor, Michigan. ENDRA also has a digital asset treasury strategy managed with Arca Investment Management, focused on holding one to five decentralized finance digital assets, initially including HYPE. Its technology platform is also being developed for applications such as thermal ablation monitoring, vascular imaging, and tissue perfusion analysis.
Price · $NDRAvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 0
- Bearish
- 1
Insider · 30dAll trades →
No SEC Form 4 filings for $NDRA in the last 30 days.
See all $NDRA insider activity →Top stories · $NDRAMore →
·tradingview.com
ASP Isotopes Plans to Vote on Merger at ENDRA Life Sciences with 15.1% Stake
ASP Isotopes Inc. disclosed a 15.1% stake in ENDRA Life Sciences Inc. and plans to vote on a merger. The investor may buy or sell more shares based on developments. ASP Isotopes focuses on critical materials production. ENDRA's special meeting is upcoming.
·tradingview.com
ENDRA Life Sciences Amends Renergen Merger; Cash Floor Set at $3.8M and Board Declassification
ENDRA Life Sciences amended its merger agreement with Renergen, setting a $3.8M cash floor and removing board classification. It also lifted a 4.99% ownership cap on warrants held by LHE LNG Holdings. The changes aim to streamline the merger and enhance financing flexibility.
NDRA sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NDRA (ENDRA Life Sciences Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent NDRA coverage spans mergers & acquisitions, earnings and corporate actions.
What's driving NDRA
Earnings preview suggests potential downside pressure if results miss the negative EPS estimate.
ASP Isotopes Inc. disclosed a 15.1% stake in ENDRA Life Sciences Inc. and plans to vote on a merger. The investor may buy or sell more shares based on developments. ASP Isotopes focuses on critical materials production. ENDRA's special meeting is upcoming.
The amendment improves financing flexibility and may be viewed positively by investors.
Amendments may affect dilution and financing, influencing share price ahead of the merger.
The commissioning phase signals progress toward operational revenue from the helium plant partnership.
AlphAI scores every news story that mentions NDRA with an AI model for sentiment and relevance, and aggregates insider trades from ENDRA Life Sciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $NDRA
Score
NDRA Q3'26 Earnings: EPS estimate is (0.84) USD
ENDRA Life Sciences (NDRA) will report Q3'26 earnings on November 16. Analysts expect $0 revenue and a loss of $0.84 per share.
ASP Isotopes Plans to Vote on Merger at ENDRA Life Sciences with 15.1% Stake
ASP Isotopes Inc. disclosed a 15.1% stake in ENDRA Life Sciences Inc. and plans to vote on a merger. The investor may buy or sell more shares based on developments. ASP Isotopes focuses on critical materials production. ENDRA's special meeting is upcoming.
ENDRA Life Sciences Amends Renergen Merger; Cash Floor Set at $3.8M and Board Declassification
ENDRA Life Sciences amended its merger agreement with Renergen, setting a $3.8M cash floor and removing board classification. It also lifted a 4.99% ownership cap on warrants held by LHE LNG Holdings. The changes aim to streamline the merger and enhance financing flexibility.
ENDRA Life Sciences Inc. (NDRA): Entry into a Material Definitive Agreement
ENDRA Life Sciences Inc. (NDRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. First Amendment to Agreement and Plan of Merger As previously disclosed, on June 25, 2026, ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger
ENDRA Life Sciences (NASDAQ: NDRA) shares ASP Isotopes helium plant update
ENDRA Life Sciences (NDRA) reported that ASP Isotopes' partner, Tetra4, has entered the commissioning phase of a liquid helium plant at the Virginia Gas Project. The announcement was made in a press release on August 20, 2026, and includes forward-looking statements under U.S. securities laws.
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (NDRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 17, 2026 ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update ANN ARBOR, Mich., (BUSINESS WIRE) – ENDRA Life Sciences Inc . (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for e
Noble Africa-ENDRA (NDRA) merger to create pure-play helium and LNG company
ASP Isotopes plans to merge its subsidiary Noble Africa, which holds South Africa’s Renergen helium and LNG project, with ENDRA Life Sciences to form a publicly listed helium platform called Noble Africa. ASP Isotopes expects ~89% ownership post-close. Management cites 1P helium reserves of 7.2 Bcf and targets Phase 1 output of ~70 Mcf/day helium and 2,500 GJ/day LNG, with estimated revenue and cash gross profit. Closing is targeted for Q4, subject to SEC review and approvals.
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
ASP Isotopes (NASDAQ:ASPI) and ENDRA Life Sciences (NASDAQ:NDRA) said RedChip will host a July 21, 2026 webinar on Noble Africa, an ASP Isotopes subsidiary holding Renergen’s Virginia Gas Project. The proposed merger with ENDRA could list Noble Africa on Nasdaq as NOBA. CEO Paul Mann will discuss helium and LNG plans, including Phase 1 ramp in 2026.
ENDRA Life Sciences Inc. (NDRA): Entry into a Material Definitive Agreement
ENDRA Life Sciences Inc. (NDRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029523901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JUNE 25, 2026, BY AND AMONG ENDRA LIFE SCIENCES INC., KRUGER MERGER SUB LLC, RENERGEN LIMITED, NOBLE AFRICA LLC AND ASP ISOTOPES INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ASP ISOTOPES INC., NO
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech
ENDRA Life Sciences (NASDAQ: NDRA) is distinguishing itself through its combination of breakthrough medical imaging innovation, specifically the TAEUS® system for liver disease, and a next-generation treasury strategy managed by Arca Investment Management. This strategy aims to improve capital efficiency and accelerate growth by transforming idle cash into a yield-generating engine. The company's TAEUS® system targets steatotic liver disease and MASH, a massive and underdiagnosed market, aligning with the rapidly expanding GLP-1 therapy market.